NHLBI Logistical Support Services

抗逆转录病毒疗法(ART)的成功开启了艾滋病毒流行的新纪元。艾滋病毒携带者(PLWH)如果接受有效的抗逆转录病毒治疗，可以达到接近正常的寿命，在这种情况下，他们更有可能遭受与艾滋病毒相关的慢性合并症、合并感染和并发症(CCCS)，而不是艾滋病定义的疾病。尽管抗逆转录病毒治疗取得了成功，但需要了解艾滋病毒的影响、其治疗以及慢性免疫激活和免疫抑制的遗留问题，以优化PLWH的健康。到目前为止，NIH的努力大多针对特定领域，很少有同时涵盖对多个器官系统或疾病的影响的倡议。需要在国家卫生研究院范围内进行科学磋商，以便更好地了解共同机制，找出研究艾滋病毒相关CCCS的差距和机会，并促进这一领域的跨学科合作。这种磋商的结果预计将有助于促进NIH对艾滋病毒相关CCCS研究日益增长的需求做出协调一致的反应，特别是针对未来研究的最高优先事项，并避免不同NIH ICO的重复努力和投资。本次研讨会于2019年9月19日至20日在马里兰州贝塞斯达的NIH纳彻会议中心举行，共有21个NIH ICO联合赞助。

The success of antiretroviral therapy (ART) has ushered in a new era for the HIV epidemic. People living with HIV (PLWH) can achieve nearly normal life-spans if treated with effective ART, in which case, they are more likely to suffer chronic HIV-related comorbidities, coinfections and complications (CCCs) than AIDS-defining conditions. Despite the success of ART, the impact of HIV, its treatment, and the legacy of chronic immune activation and immune suppression needs to be understood to optimize the health of PLWH. Efforts at NIH thus far have mostly targeted specific areas with few initiatives that encompass the impact on multiple organ systems or conditions simultaneously. NIH-wide scientific consultations are needed to gain a better understanding of common mechanisms, to identify gaps and opportunities for research in HIV-associated CCCs, and to foster cross-disciplinary collaborations in this area. Findings from such consultations are expected to help facilitate a coordinated NIH response to the growing needs for research on HIV-associated CCCs, specifically to target the highest priorities for future research and to avoid duplication of efforts and investments by the different NIH ICOs. A total of 21 NIH ICOs jointly sponsored this workshop, which occurred on September 19-20, 2019 at Natcher Conference Center, NIH in Bethesda, MD.